Video: LifeSprout Bringing Soft Tissue Reconstruction Alternative to Market
In 2017, more than a quarter million women in the United States will be diagnosed with invasive breast cancer, and many will have lumpectomies and mastectomies to remove their tumors and some surrounding tissue.
Though cancer-free, patients who undergo these procedures often have visible defects, even after painful reconstructive surgery, which uses soft tissue taken from another part of the body.
Unsatisfied with current practices that call for invasive reconstructive procedures, Sashank Reddy and Justin Sacks, two plastic surgeons at Johns Hopkins, teamed with Hai-Quan Mao, now the associate director of the University’s Institute for NanoBioTechnology, and Russ Martin, a postdoctoral fellow in Mao’s lab, to create something better.
The team developed a nanofiber-hydrogel composite material that immediately restores three-dimensional volume, feels like your body’s own soft tissue and can promote tissue regeneration over time. Importantly, while the material retains the shape and structural integrity of native tissue, it can be administered in the office through a simple injection.
Soon after, they co-founded LifeSprout and began working with Johns Hopkins Technology Ventures (JHTV) to help bring their novel technology to patients faster. LifeSprout aims to develop a suite of products to address soft tissue needs in the aesthetic and reconstructive markets.
The startup is soon to be a tenant of the FastForward 1812 innovation hub and has taken advantage of the Cohen Translational Engineering Fund and the Louis B. Thalheimer Fund for Translational Research.
The video below tells LifeSprout’s story through the eyes of Kundry Grove, a breast cancer patient who underwent reconstructive surgery.